This is a routine proxy notice with no material financial or operational news. The proposed 1,500,000 share increase to the equity plan is modest for a $13M market cap company and is standard practice. Monitor the actual vote outcome and any subsequent 8-K for dilution details, but no immediate trading action is warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $1.06entry
- T+1 · 3mo ago −0.94%α −0.27% · $1.05
- T+5 · 3mo ago +10.38%α +11.57% · $1.17
- T+20 · 2mo ago −3.77%α −1.80% · $1.02
- T+60 · 7d ago −23.23%α −20.28% · $0.8138
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phio Pharmaceuticals Corp. filed a DEFA14A (additional definitive proxy soliciting materials) for its 2026 Annual Meeting of Stockholders to be held on September 28, 2026. The filing is a routine notice providing instructions for accessing proxy materials and voting online, with the Board recommending votes FOR all six director nominees, ratification of Grant Thornton as auditor, and approval of a 1,500,000 share increase to the 2020 Long Term Incentive Plan. No financial results, activist activity, or material corporate events are disclosed.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for September 28, 2026, held virtually.
- Record date for voting is August 4, 2026.
- Board recommends FOR election of six director nominees: Robert J. Bitterman, Patricia A. Bradford, David H. Deming, Jonathan E. Freeman, Curtis A. Lockshin, and R. Todd Plott.
- Board recommends FOR ratification of Grant Thornton, LLP as independent auditor for FY 2026.
- Board recommends FOR amendment to 2020 Long Term Incentive Plan to increase shares available by 1,500,000.
- Filing is a routine DEFA14A notice; no financial data or material events reported.
Financial Impact
No financial figures reported in this filing.
Risk Factors
- Potential dilution from 1,500,000 share increase to the equity plan, though amount is small relative to market cap.
- No financial or operational updates in this filing; risk of negative news at the meeting or in future filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001683168-26-006474 |
| Document: 0001683168-26-006474-index-headers.html | 0001683168-26-006474 |
| Document: 0001683168-26-006474-index.html | 0001683168-26-006474 |
| Document: 0001683168-26-006474.txt | 0001683168-26-006474 |
Track record
7 reports on PHIO
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.8013 to $0.7710 Now $0.7520 +6.15% ▲ +3.78% +6.38% vs SPY
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $0.9345 to $0.8921 Now $0.7520 −19.53% ▼ −4.54% −3.39% vs SPY
- Sep 14, 20269w ago 8-K Bullish 5/10 Entry $1.03 to $1.01 Now $0.7520 −26.99% ▼ −1.94% −2.05% vs SPY
- Aug 14, 202613w ago DEFA14A Neutral 3/10 Viewing Entry $1.06 to $1.17 Now $0.7520 −29.06% ▲ +10.38% +11.57% vs SPY
- Apr 8, 202631w ago 8-K Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Apr 8, 202631w ago 424B5 Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Mar 5, 202636w ago 8-K Mixed 6/10 Entry $1.16 to $1.17 Now $0.7520 −35.17% ▲ +0.86% +2.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers